LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen has downgraded LENZ Therapeutics (NASDAQ:LENZ) from a “hold” to a “sell” rating. This follows a similar downgrade by Weiss Ratings, although the consensus among analysts still rates the stock as a “Moderate Buy” with an average target price of $56.40. The article also details the company’s stock performance, institutional investor holdings, and company profile.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)